WDR5 and cancer: Leaving a portion of WDR5 activities intact may inherently curb the anti-tumor activities of WINi, but it may also underlie the safety of these agents and could contribute to their efficacy, especially if interaction partners that load on to WDR5 in response to WINi contribute to cancer cell inhibition [76].